Novel methods of treating hearing loss
US-2024390323-A1 · Nov 28, 2024 · US
Uses of sesquiterpene lactone compounds and their derivatives in drugs preparation
US10463644B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10463644-B2 |
| Application number | US-201315110592-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 15, 2013 |
| Priority date | Jul 15, 2013 |
| Publication date | Nov 5, 2019 |
| Grant date | Nov 5, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the uses of sesquiterpene lactone compounds and their derivatives in preparing drugs. It belongs to the field of drug technology, specifically relates to the uses of the compounds of Formula (I) in preparing the drugs, especially the uses in preparing the drugs to treat rheumatoid arthritis and treat cancers through inhibiting cancer stem cells.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating rheumatoid arthritis in a patient comprising administering a therapeutically effective amount of compound of formula I Formula (I) t o a patient in need of rheumatoid arthritis treatment wherein the compounds of Formula I are selected from the group consisting of and wherein the compound of formula (I) are formulated in the form of injections, tablet, or capsule and administered in a therapeutically effective amount to reduce a content of TNF-α, PGE2 and IL-1β.
Assignees
Inventors
Classifications
containing a five-membered ring with oxygen as a ring hetero atom · CPC title
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
Ortho-condensed systems · CPC title
condensed with a ring other than six-membered · CPC title
having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10463644B2 cover?
- The present invention relates to the uses of sesquiterpene lactone compounds and their derivatives in preparing drugs. It belongs to the field of drug technology, specifically relates to the uses of the compounds of Formula (I) in preparing the drugs, especially the uses in preparing the drugs to treat rheumatoid arthritis and treat cancers through inhibiting cancer stem cells.
- Who is the assignee on this patent?
- Accendatech, Univ Nankai
- What technology area does this patent fall under?
- Primary CPC classification A61K31/365. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).